Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report.

Shinji Kawabata, Shin-Ichi Miyatake, Ryo Hiramatsu, Yuki Hirota, Shiro Miyata, Yoko Takekita, Toshihiko Kuroiwa, Mitsunori Kirihata, Yoshinori Sakurai, Akira Maruhashi, Koji Ono

Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2012;69(12):1796-9

PMID: 21459588

Full Text on Elsevier Science View on PubMed

Abstract

Recently, we reported our clinical experiences of boron neutron capture therapy (BNCT) for the newly diagnosed glioblastoma. The major differences of our protocol from the other past studies were simultaneous use of both sodium borocapate and boronophenylalanine, and combination with fractionated X-ray irradiation. These results showed the efficacy of combination therapy with external beam X-ray irradiation and BNCT. For our future study, we planned the multi-centric phase II clinical study for newly diagnosed glioblastoma patients in Japan (OSAKA-TRIBRAIN0902, NCT00974987).

Address: Department of Neurosurgery, Osaka Medical College, Takatsuki, Osaka, Japan. [email protected]

DOI: 10.1016/j.apradiso.2011.03.014

Link outs

Free resources

Medical:

Miscellaneous:

https://assays.cancer.gov/CPTAC-68

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0969...

MeSH Terms: Antineoplastic Agents, Boron Neutron Capture Therapy, Brain Neoplasms, Combined Modality Therapy, Dacarbazine, Glioblastoma, Humans, Temozolomide